Company Analysis
Sign in

Karyopharm Therapeutics Inc. (KPTI)

Nasdaq: KPTI · Pharmaceutical Preparations · Newton, MA · filing with the SEC since 2010
Full chart Alerts Compare
Grade3.8
◀ Past 3.7● Present 3.6▶ Future 4.3
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Karyopharm Therapeutics Inc.

Nine metrics read from its own filings, by tense
Headline grade
3.8/10
◀ Past3.730% of the headline
● Present3.640% of the headline
▶ Future4.330% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.7/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
0.1/10

Has it survived what it has been through?

6 warning events since 2017; the latest 2026-11-05.

weight 33% of this tense · 1st percentile among 497 sector filers · read for itself

From the record

Karyopharm Therapeutics Inc.'s filings since 2017 show 6 warning events of 3 kinds: a bankruptcy or receivership notice (8-K item 1.03, the latest 2026-11-03); a debt default or acceleration notice (8-K item 2.04, 2 times, the latest 2026-11-03); a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2026-11-05) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
6.0/10

What has it actually done, year after year?

+114.2% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 60th percentile among 323 sector filers · read for its customers

From the record

Karyopharm Therapeutics Inc.'s 10 filed years say what it did: revenue went from $154 thousand in fiscal 2016 to $146 million in fiscal 2025, up 114.2% a year; it rose in 6 of 9 years; the deepest fall was 31% from fiscal 2021 to fiscal 2024; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span114.2%top 8% of its family
  • the share of years revenue rosetop 41% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak30.8%top 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
4.5/10

How has it treated the people who own it?

SI estimate 4.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 45th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 45% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Karyopharm Therapeutics Inc.'s shareholder treatment is put at 4.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 45% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.6/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
2.2/10

Is it financially healthy right now?

Leverage 370%: owes 370¢ per asset dollar.

weight 45% of this tense · 22nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Karyopharm Therapeutics Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 370 cents per dollar of assets, and net share issuance: its share count grew 29.3% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 1% of its family
  • the share count against the year beforebottom 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
5.0/10

How strong is its position in its industry?

top 50% of 315 in its family; net margin -134.2%.

weight 33% of this tense · 50th percentile among 315 sector filers · read for its customers

From the record

Karyopharm Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $146 million in fiscal 2025 ranks in the top 32% by size; a net margin of -134.2% ranks in the top 49%; revenue growth of -2.4% a year over the last 3 filed years ranks in the bottom 33% (its annual reports).

What it rests on

  • revenue against the family$146Mtop 32% of its family
  • net margin-134.2%top 49% of its family
  • three-year revenue growth-2.4%bottom 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
4.2/10

What are the people in charge doing?

bottom 42% of 315 in its family for leadership; chief executive since 2021.

weight 22% of this tense · 42nd percentile among 315 sector filers · read for its shareholders

From the record

Karyopharm Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Paulson, Richard A. (President and CEO, as filed), filing under that title since 2021-05-04, 5.5 years (top 45% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 45%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge11 in three years among 13 peoplebottom 17% of its family
  • the median years the people in charge have filed5.9 yearstop 45% of its family
  • the chief executive's years on the record5.5 yearstop 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.3/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.7/10

How much room does it have to grow?

top 43% of 273 in its family for room to expand.

weight 45% of this tense · 57th percentile among 273 sector filers · read for itself

From the record

Karyopharm Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $61 million against no long-term debt tagged leaves 55.8% of its assets as net cash, top 30% of its family; cash from operations less capital spending is -51.6% of revenue (top 45%); research spending of 86% of revenue (bottom 46%) (its annual report).

What it rests on

  • cash less debt against assets55.8%top 30% of its family
  • cash from operations less capital spending against revenue-51.6%top 45% of its family
  • research spending against revenue86.0%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
2.8/10

What could actually drive growth from here?

bottom 27% of 306 in its family for growth drivers.

weight 33% of this tense · 27th percentile among 306 sector filers · read for its customers

From the record

Karyopharm Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -2.4% a year over the last three filed years against 114.2% over all 10, slowing (bottom 2% of its family); the newest year grew 0.6% (bottom 41%); research spending grew -5.5% a year (bottom 39%) (its annual reports). Karyopharm Therapeutics Inc. reported 2 product lines in fiscal 2025: Product at $115 million (79%), License and Other at $31 million (21%); 1 of 2 grew against the year before (its annual report).

What it rests on

  • three-year growth against the whole span-116.6 points a yearbottom 2% of its family
  • the newest year's revenue growth0.6%bottom 41% of its family
  • three-year growth of research spending-5.5%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
3.6/10

Did its newest year beat what its own record pointed to?

bottom 36% of 233 in its family for expectations against reality.

weight 22% of this tense · 36th percentile among 233 sector filers · read for its shareholders

From the record

Karyopharm Therapeutics Inc.'s newest year against its own record: revenue of $146 million in fiscal 2025 came in 4.6% above the $140 million its prior three years' pace pointed to (top 38% of its family); net income of $196 million against a prior three-year average of $128 million (bottom 25%); a net margin of a loss larger than its revenue against -85.3% before (bottom 22%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace4.6%top 38% of its family
  • net income against the prior three years' average-53%bottom 25% of its family
  • net margin against its prior average-48.9 pointsbottom 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton KPTI · research, not advice